T1	Participants 19 36	prostatic cancer.
T2	Participants 155 206	previously untreated patients with prostatic cancer
T3	Participants 611 684	patients with advanced disease no longer responsive to hormonal treatment
T4	Participants 794 823	Procarbazine treated patients
